Current stock page

Stock Analysis

Replimune Group, Inc. (REPL) Stock Analysis

Replimune Group, Inc. (REPL) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

REPL Stock Analysis Summary

Replimune Group, Inc. (REPL) currently has an AIQ Score of 60/100, indicating a neutral setup. Momentum is the strongest factor at 97/100. Risk is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data

REPL at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$21.89
AIQ Score60/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Buy
Market Cap$2.3B
P/E Ratio (TTM)-7.85
Forward P/E—
EPS (Q2 FY2027)-$0.54
Revenue (Q2 FY2027)$0
Dividend Yield (TTM)0.00%
Beta0.9
Volume2.02M
52-week range$1.50-$23.54
RSI 1472.07
50-Day SMA$14.76
200-Day SMA$10.00
Analyst Price Target$30.00
Next EarningsFeb 2, 2027
As of Nov 13, 2026 · Market close

REPLReplimune Group, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$21.89−$0.09 (−0.41%)

Latest quote

  • Momentum
    97
  • Value
    —
  • Quality
    35
  • Risk resilience
    26
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

REPL Stock Analysis Summary

Replimune Group, Inc. (REPL) currently has an AIQ Score of 60/100, indicating a neutral setup. Momentum is the strongest factor at 97/100. Risk resilience is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Nov 13, 2026 · Market-close data
AIQ Composite Posture: Neutral

In a neutral regime, REPL has AIQ Score of 60/100 with Momentum base of 97/100 and fading Risk resilience at 26/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Momentum (97/100) leads while Risk resilience (26/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.41% stock move · REPL classified in Biotechnology.

Current Evidence

NeutralREPL is in a neutral AIQ regime; Momentum is the strongest visible factor at 97/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is REPL Bullish or Bearish Right Now?

REPL currently has a neutral overall setup. Momentum is the strongest factor at 97/100, while Risk Resilience is weakest at 26/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Momentum is constructive at 97/100.
  • - Price is +48.27% above its 50-day SMA.
  • - Analyst target implies +37.05% upside from the latest quote.
  • - Technical consensus has more buy votes than sell votes (36 vs 7).
Bear Case
  • - Risk Resilience is weak at 26/100.

Current Consensus

REPL's Technical Analysis Consensus is currently Strong Buy, with 36 buy, 3 neutral, and 7 sell votes. REPL's 14-day RSI is 72.07, which places the stock in an overbought momentum range. REPL's beta is 0.9, indicating market sensitivity broadly in line with the market.

Signal Confidence
High agreement

What Changed in REPL?

The largest recent change in REPL is AIQ Score moving up by 1.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.

AIQ Score
+1.0
Momentum
+1.0
Quality
+0.0
Risk
+1.0

What Would Change the REPL Outlook?

The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

REPL Decision Framework

Public evidence layers, setup checks, and risk context for Replimune Group, Inc..

Replimune Group, Inc. (REPL) Stock Analysis

Replimune Group, Inc. has an AIQ Score of 60/100 in a Neutral regime. Momentum is strongest at 97/100. Beta is 0.9, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextREPL is in a Neutral AIQ regime with score 60/100.
Signal ConflictThe primary conflict is that momentum leads at 97/100 while risk lags at 26/100.
Factor EvidenceMomentum 97/100 · Quality 35/100 · Risk 26/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Momentum is the strongest factor at 97/100.

TimingPass

Momentum is 97/100 and RSI (14) is 72.1.

Regime fitWait

REPL is in a Neutral regime at 60/100.

Risk controlFail

Risk factor is 26/100 with beta 0.9 and annual volatility 187.93%.

ConflictWait

Current conflict: momentum leads at 97/100 while risk lags at 26/100.

AIQ Score
60/100
Price
$21.89
Beta
0.9
RSI (14)
72.1

REPL Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

REPL Fundamentals

REPL valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$0
Net income
-$57.12M
Free cash flow
-$47.78M
View full REPL fundamental analysis

REPL Technical Analysis

REPL technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Buy
RSI 14
72.07
Price vs SMA-50
+48.27%
View full REPL technical analysis

REPL Stock Catalysts

Track REPL earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Feb 2, 2027
Analyst target
$30.00
News items
5
View REPL earnings and stock catalysts

REPL Dividend Analysis

REPL dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
—
Payout ratio
—
View REPL dividend history and analysis

REPL Financial Data

REPL revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$0
EPS
-$0.54
Periods
8
View REPL financials

REPL Risk Analysis

REPL volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
0.9
Risk score
26/100
1Y volatility
187.93%
View REPL risk analysis

REPL Stock News

REPL stock news, market tone, recent headlines, and catalyst context.

News items
5
Updated
Nov 15, 2026
Sentiment
—
Read REPL stock news

REPL vs Biotechnology Peers

Current peer cohort: REPL · RLAY · RVMD · RYTM · SEPN. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
REPL
Current stock
60/100—97/10026/1001.3187.93%Current
RLAY
Relay Therapeutics, Inc.
56/10037/10076/10052/1001.8465.80%REPL vs RLAY
RVMD
Revolution Medicines, Inc.
55/10039/10073/10059/1001.6968.69%REPL vs RVMD
RYTM
Rhythm Pharmaceuticals, Inc.
62/10052/10072/10057/1000.5254.57%REPL vs RYTM
SEPN
Septerna Inc
69/10055/10087/10052/1001.4369.35%REPL vs SEPN
Pairwise Compare links: RLAY · RVMD · RYTM · SEPNREPL vs RLAYREPL vs RVMDREPL vs RYTMREPL vs SEPNCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Nov 13, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a REPL stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

Also for REPL: historical return with reinvested dividends and stock average calculator for several buys.

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Nov 16, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
-7.85
As of Nov 13, 2026
Revenue growth
—
Gross margin
0.00%
Current debt / equity
0.62
Latest quarterly evidence

Latest period Sep 30, 2026.

Review fundamentals
Quarter revenue
$0
Quarter net income
-$57.12M
Quarter free cash flow
-$47.78M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bullish
Momentum
Bullish
RSI 14
72.07
MACD
2.5

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
26/100
Beta
0.9
Annual volatility
187.93%
Max drawdown
-84.16%

REPL Stock FAQ

What is REPL stock price today?

Replimune Group, Inc.'s current stock price is $21.89. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is REPL bullish or bearish right now?

REPL's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is REPL's market cap?

REPL's market cap is $2.3B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is REPL's current P/E ratio?

REPL's current P/E ratio is -7.85 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is REPL's RSI?

REPL's 14-day RSI is 72.07 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is REPL above its 50-day and 200-day moving averages?

REPL is 48.27% from its 50-day SMA and 118.86% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is REPL's next earnings date?

REPL's next earnings date is currently listed as Feb 2, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does REPL pay a dividend?

REPL's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.